Respiratory News and Research

RSS

Multivalent nanobodies show improved neutralization activity against SARS-CoV-2

A state-of-the-art engineering approach toward improving the neutralizing activity of a cross-reactive nanobody, previously generated against the original SARS virus, showed it can be an attractive and viable option against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The study is published in the journal Advanced Therapeutics.

5 Aug 2021

New method for producing pseudotyped virus particles bearing spike protein of SARS-CoV-2

A new study discusses the development of an improved protocol based on cell lines that can consistently express S proteins.

5 Aug 2021

Activation of NLRP3 inflammasome by the N protein of SARS-CoV-2 to induce hyperinflammation

A new study has revealed the mechanism by which the SARS-CoV-2 N protein activates NLRP3 inflammasomes to induce hyperinflammation.

5 Aug 2021

COVID vaccines generate antibodies in saliva

Researchers in the United States and Canada have conducted a study showing that the vaccines developed by Pfizer-BioNTech and Moderna to protect against coronavirus disease 2019 (COVID-19) generate local antibody responses in the salivary gland that are independent of the systemic immune response.

5 Aug 2021

Vaccination may protect against SARS-CoV-2 infection at the eye surface

Researchers in Australia have conducted a study showing that vaccination against coronavirus disease 2019 (COVID-19) induces key antibodies at the eye surface that may help to protect against the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

5 Aug 2021

Specific and sensitive biomarker in the blood predicts symptomatic COVID-19 infection

Researchers remain perplexed as to why some patients infected with SARS-CoV-2, the virus responsible for COVID-19, remain asymptomatic while other patients develop severe disease symptoms.

5 Aug 2021

Nine things parents should know about the Delta variant to keep children safe as schools reopen

Despite the rise in Delta variant cases, increased hospitalizations and reinstated mask mandates, many schools are set to reopen as early as next week.

5 Aug 2021

A correlation study between time-from-vaccine and SARS-CoV-2 breakthrough infections

A new retrospective study compares the incidence rates of breakthrough infections between different time points at which individuals were vaccinated.

5 Aug 2021

Vaccinia-based COVID-19 vaccines confer immunity in hamster model

In a paper recently uploaded to the preprint server bioRxiv* by Kulkarni et al. (August 3, 2021), the potential of vaccinia virus-based vaccines expressing the full-length SARS-CoV-2 spike protein is examined in mice and Syrian hamsters. The findings report that the vaccine generates high titers of neutralizing antibodies with good activity towards SARS-CoV-2 variants of concern.

5 Aug 2021

Immunocompromised patients could be potential hosts for immune-escape mutants of SARS-CoV-2

In a recently published article in The New England Journal of Medicine, scientists have described how multi-mutational variants of SARS-CoV-2 may evolve in patients with immunosuppression.

5 Aug 2021

How does the mRNA/lipid nanoparticle platform promote protective adaptive immunity against SARS-CoV-2?

Modified mRNA combined with lipid nanoparticles may be beneficial in boosting adaptive immunity against SARS-CoV-2. Research led by Botond Z. Igyártó from Thomas Jefferson University’s Department of Microbiology and Immunology in Pennsylvania recently found that the lipid nanoparticles induce protective adaptive immune responses with antibody titers against lethal doses of the virus.

5 Aug 2021

Could a plant metabolite in liverworts be a potent antiviral against SARS-CoV-2 and other RNA viruses?

A new study from the National Centre for Biotechnology and Medicinal Chemistry Institute suggests Mother Nature delivered — in the form of liverworts. They found that the bryophyte Marchantia polymorpha, also known as umbrella liverworts, could work as a potential antiviral treatment.

5 Aug 2021

Two monoclonal antibodies broadly neutralize SARS-CoV-2 variants of concern

Researchers in the United States and Canada have described the structural basis and mode of action for two monoclonal antibodies that potently neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

4 Aug 2021

Monoclonal antibody could inform development of pan-coronavirus vaccines

Researchers in the United States have demonstrated the potential of a monoclonal antibody to inform the design of pan-coronavirus vaccines that could prevent the outbreak of future pandemics such as coronavirus disease 2019 (COVID-19).

4 Aug 2021

The role of natural killer cells in the fight against coronavirus infection

This study proposes a mathematical framework to analyze the effect of the viruses on type I interferon (IFN-I) signaling, which is part of the innate immune response. IFN-I brings about natural killer cell activation, which in turn causes the activation of macrophages.

4 Aug 2021

Medical associations join forces to remove regulatory barriers to noninvasive ventilation

On July 30, 2021, the journal CHEST® electronically published the outcomes and recommendations of a technical expert panel on optimal noninvasive ventilation, conducted by the American College of Chest Physicians, the American Academy of Sleep Medicine, the American Association for Respiratory Care, and the American Thoracic Society.

4 Aug 2021

Initiating therapeutic anticoagulation benefits moderately ill COVID-19 patients, but not critically ill patients

A large clinical trial conducted worldwide shows that treating moderately ill hospitalized COVID-19 patients with a full-dose blood thinner reduced their need for organ support, such as mechanical ventilation, and improved their chances of leaving the hospital.

4 Aug 2021

Respiratory News and Research

Multivalent nanobodies show improved neutralization activity against SARS-CoV-2

New method for producing pseudotyped virus particles bearing spike protein of SARS-CoV-2

Activation of NLRP3 inflammasome by the N protein of SARS-CoV-2 to induce hyperinflammation

COVID vaccines generate antibodies in saliva

Vaccination may protect against SARS-CoV-2 infection at the eye surface

Specific and sensitive biomarker in the blood predicts symptomatic COVID-19 infection

Nine things parents should know about the Delta variant to keep children safe as schools reopen

A correlation study between time-from-vaccine and SARS-CoV-2 breakthrough infections

Vaccinia-based COVID-19 vaccines confer immunity in hamster model

Immunocompromised patients could be potential hosts for immune-escape mutants of SARS-CoV-2

How does the mRNA/lipid nanoparticle platform promote protective adaptive immunity against SARS-CoV-2?

Could a plant metabolite in liverworts be a potent antiviral against SARS-CoV-2 and other RNA viruses?

Two monoclonal antibodies broadly neutralize SARS-CoV-2 variants of concern

Monoclonal antibody could inform development of pan-coronavirus vaccines

The role of natural killer cells in the fight against coronavirus infection

Medical associations join forces to remove regulatory barriers to noninvasive ventilation

Initiating therapeutic anticoagulation benefits moderately ill COVID-19 patients, but not critically ill patients

Flu vaccine may provide vital protection against COVID-19, study shows

Study finds only 15% of rural health care workers have SARS-CoV-2 antibodies

Heterologous prime-boost vaccination induces robust mucosal and systemic immunity against SARS-CoV-2

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News